ArticleDiagnostics (Basel, Switzerland)2024
A Machine Learning Model for the Prediction of No-Reflow Phenomenon in Acute Myocardial Infarction Using the CALLY Index.
Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07203573 (Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index on Patients Undergoing Primary Percutaneous Coronary Intervention
Who cites it
10 citing papers in PubMed.
- Lower Admission CALLY Index Is Associated with Contrast-Associated Acute Kidney Injury in Patients with STEMI Undergoing Primary PCI.Medicina (Kaunas, Lithuania) · 2026Article
- The Naples Prognostic Score May Predict No Reflow in Patients Undergoing Percutaneous Coronary Intervention for Saphenous Vein Graft Stenosis.Diagnostics (Basel, Switzerland) · 2026Article
- Machine Learning-Based Prediction of Long-Term Mortality in STEMI Patients Using Clinical, Laboratory, and Inflammatory-Metabolic Indices.Journal of clinical medicine · 2026Article
- Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for 1-Year Mortality After Transcatheter Aortic Valve Implantation.Journal of cardiovascular development and disease · 2026Article
- Artificial intelligence in the cath lab: Bridging predictive models and real-time procedural decision support.EXCLI journal · 2026Review
- Prognostic value of CALLY index in combination with the GRACE score among patients with acute myocardial infarction: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- The CALLY index in cancer research: a comprehensive review.Oncology reviews · 2026Review
- Novel insights into no-reflow post-PCI: The predictive value of coronary sinus hemodynamics.Global cardiology science & practice · 2025Article
- A Multitask Deep Learning Model for Predicting Myocardial Infarction Complications.Bioengineering (Basel, Switzerland) · 2025Article
- The Predictive Value of ALBI Score for No-Reflow in Non-ST Elevation Acute Coronary Syndrome.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myocardial infarction (AMI) constitutes a major health problem with high mortality rates worldwide. In patients with ST-segment elevation myocardial infarction (STEMI), no-reflow phenomenon is a condition that adversely affects response to therapy. Previous studies have demonstrated that the CALLY index, calculated using C-reactive protein (CRP), albumin, and lymphocytes, is a reliable indicator of mortality in patients with non-cardiac diseases. The objective of this study is to investigate the potential utility of the CALLY index in detecting no-reflow patients and to determine the predictability of this phenomenon using machine learning (ML) methods.
methodsThis study included 1785 STEMI patients admitted to the clinic between January 2020 and June 2024 who underwent percutaneous coronary intervention (PCI). Patients were in no-reflow status, and other clinical data were analyzed. The CALLY index was calculated using data on patients' inflammatory status. The Extreme Gradient Boosting (XGBoost) ML algorithm was used for no-reflow prediction.
resultsNo-reflow was detected in a proportion of patients participating in this study. The model obtained with the XGBoost algorithm showed high accuracy rates in predicting no-reflow status. The role of the CALLY index in predicting no-reflow status was clearly demonstrated.
conclusionsThe CALLY index has emerged as a valuable tool for predicting no-reflow status in STEMI patients. This study demonstrates how machine learning methods can be effective in clinical applications and paves the way for innovative approaches for the management of no-reflow phenomenon. Future research needs to confirm and extend these findings with larger sample sizes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.